THE THERAPEUTIC
POTENTIAL
OF AAT
TREATMENT OF
INFLAMMATORY RESPIRATORY
DISEASES
NEW THERAPIES FOR RESPIRATORY DISEASES
AATec Medical develops a therapeutic platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of respiratory diseases. Our lead product candidate ATL-105 is an inhalation treatment for non-CF bronchiectasis, COPD, asthma, and pulmonary infections.
PROTEIN INHALATION TECHNOLOGY FOR EFFECTIVE TREATMENT
Respiratory diseases require drug delivery in the airways. Our protein formulation combined with inhalation technology allows for drug administration directly to the respiratory tract, for optimal local effect.
FOUNDED BY EXPERTS
AATec was founded by a senior team of experts from medical research, biopharmaceutical product development, industrialization and business. All have a clear vision and interdisciplinary experience.
GLOBAL
IMPACT
Respiratory diseases have global societal impact. We design our products to be available for people everywhere – accessible, affordable and with worldwide reach.
OUR PARTNERS
